Literature DB >> 17693656

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

F Farace, C Massard, E Borghi, J-M Bidart, J-C Soria.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17693656     DOI： 10.1093/annonc/mdm367

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.

Authors:  Sarika Jain; Maureen M Ward; Jennifer O'Loughlin; Marissa Boeck; Naomi Wiener; Ellen Chuang; Tessa Cigler; Anne Moore; Diana Donovan; Christina Lam; Marta V Cobham; Sarah Schneider; Paul Christos; Rebecca N Baergen; Alexander Swistel; Maureen E Lane; Vivek Mittal; Shahin Rafii; Linda T Vahdat
Journal:  Breast Cancer Res Treat       Date:  2011-12-09       Impact factor: 4.872

2.  Decrease in circulating endothelial progenitor cells in treated glioma patients.

Authors:  Elena Corsini; Emilio Ciusani; Paola Gaviani; Antonio Silvani; Alessandra Canazza; Gaetano Bernardi; Chiara Calatozzolo; Francesco DiMeco; Francesco Di Meco; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2012-02-14       Impact factor: 4.130

3.  Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

Authors:  Yuval Shaked; Terence Tang; Jill Woloszynek; Laura G Daenen; Shan Man; Ping Xu; Shi-Rong Cai; Jeffrey M Arbeit; Emile E Voest; David J Chaplin; Jon Smythe; Adrian Harris; Paul Nathan; Ian Judson; Gordon Rustin; Francesco Bertolini; Daniel C Link; Robert S Kerbel
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

4.  Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.

Authors:  Jeanine M Roodhart; Marlies H Langenberg; Joost S Vermaat; Martijn P Lolkema; Arnold Baars; Rachel H Giles; Els O Witteveen; Emile E Voest
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

Review 5.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

6.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Authors:  Yuval Shaked; Erik Henke; Jeanine M L Roodhart; Patrizia Mancuso; Marlies H G Langenberg; Marco Colleoni; Laura G Daenen; Shan Man; Ping Xu; Urban Emmenegger; Terence Tang; Zhenping Zhu; Larry Witte; Robert M Strieter; Francesco Bertolini; Emile E Voest; Robert Benezra; Robert S Kerbel
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743

Review 7.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

8.  Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.

Authors:  Shunsuke Kondo; Hideki Ueno; Jun Hashimoto; Chigusa Morizane; Fumiaki Koizumi; Takuji Okusaka; Kenji Tamura
Journal:  BMC Cancer       Date:  2012-06-25       Impact factor: 4.430

9.  Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  F Farace; M Gross-Goupil; E Tournay; M Taylor; N Vimond; N Jacques; F Billiot; A Mauguen; C Hill; B Escudier
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

10.  Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.

Authors:  R S Bhatt; A J Zurita; A O'Neill; A Norden-Zfoni; L Zhang; H K Wu; P Y Wen; D George; V P Sukhatme; M B Atkins; J V Heymach
Journal:  Br J Cancer       Date:  2011-06-14       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.